Cagrilintide
Long-Acting Amylin Receptor Agonist
Cagrilintide is a long-acting amylin receptor agonist developed by Novo Nordisk for weight management and metabolic health. It mimics the action of naturally occurring amylin hormone, which is co-secreted with insulin from pancreatic beta cells. Currently in Phase 3 clinical trials as part of CagriSema (combination with semaglutide), cagrilintide provides enhanced appetite suppression and gastric emptying control through amylin pathway activation.
Daily Implementation Guide
Daily Implementation Schedule
Lifestyle Integration Strategies
Nutrition Optimization
- •High-protein meals (30-40g per meal)
- •Eat slowly to enhance satiety effects
- •Stay hydrated (3+ liters daily)
- •Avoid high-fat meals on injection day
Exercise Enhancement
- •Start with 150 min moderate exercise weekly
- •Resistance training 2-3x per week
- •Monitor energy levels during escalation
- •Adjust intensity based on side effects
Sleep & Recovery
- •Maintain consistent sleep schedule
- •Monitor for sleep quality improvements
- •Track energy levels throughout day
- •Adjust injection timing if affecting sleep
Progress Tracking
SUCCESS MILESTONES
Medical Disclaimer
This information is for educational purposes only. Cagrilintide is currently in Phase 3 clinical trials and is not yet approved for commercial use. It requires prescription and medical supervision when available. This content does not constitute medical advice and should not replace consultation with qualified healthcare professionals. Participation in clinical trials may be available through clinicaltrials.gov.